Gerald Batist

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. ncbi Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy
    Gerald Batist
    Jewish General Hospital, McGill University, 3755 Cote St Catherine, Montreal, PQ, H3T 1E2 Canada
    Expert Opin Pharmacother 3:1739-51. 2002
  2. doi Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy
    Martin Loignon
    Segal Cancer Centre, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    Mol Cancer Ther 8:2432-40. 2009
  3. ncbi Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
    G Batist
    Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    J Clin Oncol 19:1444-54. 2001
  4. ncbi Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels
    G Batist
    McGill Center for Translational Research in Cancer, McGill University, Montreal, Quebec, Canada
    Ann Oncol 13:1259-63. 2002
  5. ncbi Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: resu
    Gerald Batist
    Jewish General Hospital, McGill University Department of Oncology, Montreal, Quebec, Canada, Duke University Medical Center, Durham, North Carolina, USA
    Anticancer Drugs 17:587-95. 2006
  6. ncbi Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells
    Ala Eddin Al Moustafa
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    Oncogene 23:5252-6. 2004
  7. doi Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study
    Martine T E Puts
    McGill University Université de Montréal Solidage Research Group on Frailty and Aging, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    Drugs Aging 27:559-72. 2010
  8. ncbi Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies
    Liangao Hu
    Department of Oncology, Segal Cancer Centre, Lady Davis Institute for Medical Research, Center for Experimental Therapeutics in Cancer, Sir Mortimer B Davis Jewish General Hospital, McGill University, 3755 Cote Sainte Catherine Road, Montreal, QC, H3T 1E2, Canada
    Cancer Chemother Pharmacol 66:467-74. 2010
  9. doi Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target
    Andrew Bier
    Department of Oncology, Segal Cancer Centre, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, and Department of Biochemistry and McGill Cancer Centre, McGill University, Montreal, Quebec, Canada H3T 1E2
    Mol Cancer Ther 8:786-93. 2009
  10. doi Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study
    Martine T E Puts
    Solidage Research Group on Frailty and Aging, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada
    Crit Rev Oncol Hematol 78:138-49. 2011

Detail Information

Publications68

  1. ncbi Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy
    Gerald Batist
    Jewish General Hospital, McGill University, 3755 Cote St Catherine, Montreal, PQ, H3T 1E2 Canada
    Expert Opin Pharmacother 3:1739-51. 2002
    ..The development of Myocet, a less cardiotoxic, better tolerated and equally efficacious doxorubicin, extends the therapeutic options in the overall management of breast cancer...
  2. doi Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy
    Martin Loignon
    Segal Cancer Centre, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    Mol Cancer Ther 8:2432-40. 2009
    ..This high Cul3/low Nrf2 signature may be key to cellular sensitivity to both chemical carcinogeneic stimuli as well as to cytotoxicity of commonly used chemotherapeutic drugs in established breast cancers...
  3. ncbi Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
    G Batist
    Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    J Clin Oncol 19:1444-54. 2001
    ....
  4. ncbi Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels
    G Batist
    McGill Center for Translational Research in Cancer, McGill University, Montreal, Quebec, Canada
    Ann Oncol 13:1259-63. 2002
    ..Neovastat (60 or 240 ml/day) was administered orally (b.i.d.) to 144 patients with solid tumors refractory to standard therapies or for whom no standard treatments were available...
  5. ncbi Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: resu
    Gerald Batist
    Jewish General Hospital, McGill University Department of Oncology, Montreal, Quebec, Canada, Duke University Medical Center, Durham, North Carolina, USA
    Anticancer Drugs 17:587-95. 2006
    ..This analysis revisits the therapeutic option of including doxorubicin in the treatment of MBC patients who have had prior adjuvant anthracycline exposure...
  6. ncbi Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells
    Ala Eddin Al Moustafa
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    Oncogene 23:5252-6. 2004
    ..Our data suggest that anti-cyclin D1 therapy may be highly specific in the treatment of all human cancers expressing high-risk HPVs or HPVs/ErbB-2...
  7. doi Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study
    Martine T E Puts
    McGill University Université de Montréal Solidage Research Group on Frailty and Aging, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    Drugs Aging 27:559-72. 2010
    ..Older cancer patients are possibly at an increased risk of medication-related problems because, typically, they receive many medications during their cancer treatment, both for the cancer itself and for supportive care...
  8. ncbi Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies
    Liangao Hu
    Department of Oncology, Segal Cancer Centre, Lady Davis Institute for Medical Research, Center for Experimental Therapeutics in Cancer, Sir Mortimer B Davis Jewish General Hospital, McGill University, 3755 Cote Sainte Catherine Road, Montreal, QC, H3T 1E2, Canada
    Cancer Chemother Pharmacol 66:467-74. 2010
    ....
  9. doi Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target
    Andrew Bier
    Department of Oncology, Segal Cancer Centre, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, and Department of Biochemistry and McGill Cancer Centre, McGill University, Montreal, Quebec, Canada H3T 1E2
    Mol Cancer Ther 8:786-93. 2009
    ..Our results show that PsiCx43 acts as a posttranscriptional regulator of Cx43 in breast cancer cells, and that this represents an example of the regulation of genes by pseudogenes with potential therapeutic implications in cancer...
  10. doi Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study
    Martine T E Puts
    Solidage Research Group on Frailty and Aging, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada
    Crit Rev Oncol Hematol 78:138-49. 2011
    ..The concept of frailty may be useful to characterize vulnerability. The aim of this pilot study was to explore the association between frailty/functional status and treatment toxicity at 3 months and mortality at 6 months...
  11. doi Characteristics of older newly diagnosed cancer patients refusing cancer treatments
    Martine T E Puts
    McGill University Université de Montréal Solidage Research Group on Frailty and Aging, Montreal, QC, Canada
    Support Care Cancer 18:969-74. 2010
    ..The aim of this paper was to describe the health and functional status characteristics of patients who refused cancer treatment...
  12. ncbi A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells
    Maite Hernandez
    Departments of Medicine, Oncology, and Pharmacology and Therapeutics, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, 3755 Chemin de la Cote Ste Catherine, Montreal, Quebec, Canada
    Prostate 66:1151-61. 2006
    ..cx43 is frequently downregulated in prostate cancer. We investigated the role of a histone deacetylase (HDAC)-dependent mechanism in the transcriptional repression of cx43 in a panel of prostate cancer cells...
  13. ncbi Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors
    Victor Cohen
    Segal Cancer Center, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Cancer 116:4309-17. 2010
    ..Somatic mutations in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKI) in patients with nonsmall cell lung cancer (NSCLC)...
  14. ncbi Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma
    Lyndsay Harris
    Duke University Medical Center, Durham, North Carolina, USA
    Cancer 94:25-36. 2002
    ....
  15. doi Difficulties in decision making regarding chemotherapy for older cancer patients: A census of cancer physicians
    Doreen Wan-Chow-Wah
    Division of Geriatric Medicine, Jewish General Hospital, Montreal, Quebec, Canada
    Crit Rev Oncol Hematol 78:45-58. 2011
    ..The management of older cancer patients is often suboptimal. This study aims to understand the management of older cancer patients who may receive chemotherapy...
  16. ncbi Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes
    Weimin Miao
    Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, The Sir Mortimer B Davis Jewish General Hospital and Department of Oncology, McGill University, Montreal, Quebec H3T 1E2, Canada
    J Biol Chem 280:20340-8. 2005
    ..Moreover, direct regulation of NRF2 by AHR contributes to couple phase I and II enzymes into an integrated system facilitating more effective xenobiotic and carcinogen detoxification...
  17. ncbi Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine
    Zuanel Diaz
    Quebec Clinical Research Organization in Cancer, Montreal, QC, Canada
    Mod Pathol 26:1413-24. 2013
    ..Our standard operating procedures for next-generation biobanking can be applied widely in multiple settings, including multicentered and international biopsy-driven trials. ..
  18. doi Medication problems in older, newly diagnosed cancer patients in Canada: How common are they? A prospective pilot study
    Martine T E Puts
    Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Drugs Aging 26:519-36. 2009
    ..Few studies have examined the scope of this problem in older newly diagnosed cancer patients...
  19. doi Making sense of intratumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues
    Bruce Gottlieb
    Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
    Hum Mutat 34:610-8. 2013
    ....
  20. ncbi A cell-based system to identify and characterize the molecular mechanism of drug-metabolizing enzyme (DME) modulators
    Weimin Miao
    Department of Oncology, Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, 3755 Cote St Catherine Road, Montreal, Quebec, Canada H3T 1E2
    Biochem Pharmacol 67:1897-905. 2004
    ..Finally, this cell-based system permitted us to identify a potential novel mechanism for cross-talk between the ARE and the xenobiotic response element (XRE)-mediated pathways...
  21. ncbi Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1
    Jian H Wu
    Montreal Centre for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, QC, Canada
    Chem Biol Drug Des 75:475-80. 2010
    ..Further, BM31 and BM40 potently induce expression of ARE-regulated enzyme gamma-glutamylcysteine synthetase. We demonstrated that BM31 provides protections for the MCF-7 cells from cytotoxic damage of carcinogen benzo[a]pyrene...
  22. doi The relationship of self-rated health with functional status, toxicity and mortality: results of a prospective pilot study of older patients with newly-diagnosed cancer
    Martine Puts
    Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada Solidage Research Group on Frailty and Aging, Jewish General Hospital, Montreal, Canada Electronic address
    J Geriatr Oncol 4:319-26. 2013
    ..To determine the association between self-rated health (SRH) and functional status, comorbidity, toxicity of treatment and mortality in older patients with newly-diagnosed cancer...
  23. ncbi Novel use of the fluorescent dye 5-(and-6)-chloromethyl SNARF-1 acetate for the measurement of intracellular glutathione in leukemic cells and primary lymphocytes
    David Hamilton
    Department of Pharmacology and Therapeutics, The Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Cytometry A 71:709-15. 2007
    ..80-0.88. CM-SNARF can be used to semi-quantitatively and rapidly determine intracellular variations in GSH concentration in the range of 10-150 nmoles GSH/mg protein...
  24. doi Syntheses and potential anti-prostate cancer activities of ionone-based chalcones
    Jinming Zhou
    Department of Oncology, McGill University, Montreal, Canada
    Bioorg Med Chem Lett 19:1183-6. 2009
    ....
  25. ncbi Structure-based identification of novel human gamma-glutamylcysteine synthetase inhibitors
    David Hamilton
    Department of Oncology, McGill University, Montreal Centre for Experimental Therapeutics in Cancer and Segal Cancer Centre, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    Mol Pharmacol 71:1140-7. 2007
    ..This work validates the use of model-based database mining and identified inhibitors of gamma-GCS(H) with novel chemical structures...
  26. ncbi Connexin43 pseudogene is expressed in tumor cells and inhibits growth
    Mustapha Kandouz
    Department of Oncology, Montreal Centre for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, McGill University, Montreal, Quebec, Canada H3T 1E2
    Oncogene 23:4763-70. 2004
    ..Based on our findings, PsiCx43 joins and enlarges the thus far restricted group of functionally transcribed and translated pseudogenes...
  27. pmc Participation of older newly-diagnosed cancer patients in an observational prospective pilot study: an example of recruitment and retention
    Martine T E Puts
    Solidage Research Group, Université de Montréal McGill University Research Group on Frailty and Aging, Montreal, Canada
    BMC Cancer 9:277. 2009
    ..This paper reports on strategies to recruit older newly-diagnosed cancer patients prior to treatment into an observational prospective pilot study and to retain them during a six-month period...
  28. ncbi Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues
    P James Scrivens
    Lady Davis Institute for Medical Research, SMBD Jewish General Hospital, Montreal, Quebec, Canada
    Mol Cancer Ther 2:1053-9. 2003
    ....
  29. ncbi Anthracyclines
    David Hamilton
    Department of Pharmacology and Therapeutics, The Montreal Center for Experimental Therapeutics in Cancer, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    Cancer Chemother Biol Response Modif 22:19-33. 2005
  30. ncbi The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity action
    Khadidja Haidara
    Department of Oncology, Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, McGill University, Montreal, Que, Canada H3T 1E2
    Cancer Lett 242:180-90. 2006
    ..A number of features suggest that Casticin could be important in cancer therapy. Indeed, Pgp over expressing cells are not resistant to Casticin, and its cell killing effect is observed even in p53 mutant or null cell lines...
  31. doi Glutathione and glutathione analogues; therapeutic potentials
    Jian Hui Wu
    McGill University, Canada
    Biochim Biophys Acta 1830:3350-3. 2013
    ..Glutathione (GSH) and related enzymes are critical to cell protection from toxins, both endogenous and environmental, including a number of anti-cancer cytotoxic agents...
  32. ncbi The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways
    Mustapha Kandouz
    Montreal Centre for Experimental Therapeutics in Cancer, Segal Cancer Centre, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, QC, Canada
    Cell Cycle 9:398-407. 2010
    ..Finally, EphB2 expression inactivates Akt, which is a known inhibitor of autophagy. In conclusion, the EphB2 receptor induces an autophagic cell death that is mediated through the ERK1/2 and PI3K/Akt pathways...
  33. doi Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors
    Gerald Batist
    Segal Cancer Center, Sir Mortimer B Davis Jewish General Hospital, Department of Oncology, McGill University, Montreal, Quebec, Canada
    Clin Cancer Res 15:692-700. 2009
    ..This open-label, single-arm, dose-escalating phase I study was designed to determine the maximum tolerated dose and pharmacokinetics of CPX-1 in patients with advanced solid tumors...
  34. ncbi Clinical experience of cancer specialists and geriatricians involved in cancer care of older patients: A qualitative study
    M T E Puts
    Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada
    Crit Rev Oncol Hematol 74:87-96. 2010
    ..Cancer is an important health problem in older persons. The aim of this study was to explore how cancer specialists and geriatricians manage the treatment of older patients with cancer...
  35. doi Biopsies: next-generation biospecimens for tailoring therapy
    Mark Basik
    Department of Surgery, Jewish General Hospital, McGill University, 3755 Cote Sainte Catherine Road, Montreal, QC H3T 1E2, Canada
    Nat Rev Clin Oncol 10:437-50. 2013
    ....
  36. ncbi TLK-199 (Telik)
    David Hamilton
    Sir Mortimer B Davis Jewish General Hospital, Department of Pharmacology and Therapeutics, McGill University, Montreal, Canada
    IDrugs 8:662-9. 2005
    ..Telik Inc is developing TLK-199, an intravenous inhibitor of glutathione S-transferase P1-1, for the potential prevention of myelosuppression in blood diseases, namely myelodysplastic syndrome...
  37. ncbi Cardiac safety of liposomal anthracyclines
    Gerald Batist
    The Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, The Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, QC, Canada
    Cardiovasc Toxicol 7:72-4. 2007
    ..A cardiac safe formulation of doxorubicin opens a number of interesting therapeutic opportunities. Liposomal doxorubicins appear to provide this opportunity...
  38. pmc Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up care
    Annett Körner
    Department of Educational and Counselling Psychology, McGill University, 3700, rue McTavish, Montreal, QC, H3A 1Y2, Canada
    BMC Dermatol 13:3. 2013
    ..The main objective of the current project is to examine psychosocial predictors of skin self-examination using on a rigorous and clinically sound methodology...
  39. pmc Systemic cancer therapy: achievements and challenges that lie ahead
    Michael O Palumbo
    Department of Medicine and Oncology, Sir Mortimer B Davis Jewish General Hospital, Segal Cancer Centre, McGill University Montreal, QC, Canada
    Front Pharmacol 4:57. 2013
    ....
  40. ncbi E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells
    Ala Eddin Al Moustafa
    Lady Davis Institute for Medical Research of the Sir Mortimer B Davis Jewish General Hospital, Department of Medicine, and Center for Translational Research in Cancer, Quebec, Canada
    Oncogene 23:350-8. 2004
    ..This conversion leads to the upregulation of cyclin D1, c-myc and other oncoproteins necessary for alteration of the E-cadherin/catenin complex and cell transformation of NOE cells...
  41. doi The impact of a multimedia informational intervention on psychosocial adjustment among individuals with newly diagnosed breast or prostate cancer: a feasibility study
    Carmen G Loiselle
    School of Nursing, Faculty of Medicine, McGill University, Montreal, Canada
    Patient Educ Couns 80:48-55. 2010
    ..To examine the impact of an 8-week cancer multimedia informational intervention on health-related outcomes among individuals newly diagnosed with cancer...
  42. ncbi Usefulness of frailty markers in the assessment of the health and functional status of older cancer patients referred for chemotherapy: a pilot study
    Frederique Retornaz
    Division of Geriatric Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    J Gerontol A Biol Sci Med Sci 63:518-22. 2008
    ..Choosing the most sensitive tools to assess their health status is a major issue. This cross-sectional study explores the usefulness of frailty markers in detecting vulnerability in older cancer patients...
  43. ncbi Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer
    Victor Cohen
    Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
    Cancer 107:2858-65. 2006
    ..The use of denaturing high-performance liquid chromatography (dHPLC) as a method to screen for the 2 predominant EGFR mutations is reported...
  44. ncbi The biology of melanoma prognostic factors
    Alan Spatz
    Department of Pathology, Segal Cancer Centre Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Discov Med 10:87-93. 2010
    ..This will lead to the development of platforms which can be used by scientists from different fields to integrate and share high-quality data in the pre-competitive setting and generate new probabilistic causal models...
  45. ncbi Oltipraz is a bifunctional inducer activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic responsive element
    Weimin Miao
    Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, The Sir Mortimer B Davis Jewish General Hospital, 3755 Cote Sainte Catherine Road, Montreal, Quebec, Canada H3T 1E2
    Mol Pharmacol 64:346-54. 2003
    ..Oltipraz is a bifunctional inducer, modulating both phase I and II drug-metabolizing enzymes to enhance carcinogen detoxification...
  46. ncbi Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells
    Ala Eddin Al Moustafa
    Lady Davis Institute for Medical Research of the Sir Mortimer B Davis Jewish General Hospital, Department of Medicine, McGill Center for Translational Research in Cancer, 3755, Ch de la Cote Ste Catherine, Montreal, Quebec, Canada H3T 1E2
    Oncogene 21:2634-40. 2002
    ..These findings provide a large body of information regarding gene expression profiles associated with head and neck carcinogenesis, and also represent a source of potential targets for HNSCC prevention and/or therapeutics...
  47. ncbi AE-941 (Neovastat): a novel multifunctional antiangiogenic compound
    D Gingras
    , , , 3175, , , , Canada
    Expert Rev Anticancer Ther 1:341-7. 2001
    ..Moreover, the median survival time in patients with renal cell carcinoma and non-small cell lung cancer was significantly longer in patients receiving high doses of AE-941 compared to low doses...
  48. ncbi Use of statins and the risk of death in patients with prostate cancer
    Oriana Yu
    Oriana Yu, Maria Eberg, Samy Suissa, and Laurent Azoulay, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital Oriana Yu, Jewish General Hospital Oriana Yu, Armen Aprikian, Gerald Batist, Samy Suissa, and Laurent Azoulay, McGill University Serge Benayoun, University of Montreal Armen Aprikian, McGill University Health Centre, McGill University Gerald Batist and Laurent Azoulay, Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada
    J Clin Oncol 32:5-11. 2014
    ....
  49. ncbi Glutathione analogues in cancer treatment
    David Hamilton
    Department of Pharmacology and Therapeutics, The Montreal Center for Experimental Therapeutics in Cancer, Room D127, Sir Mortimer B Davis Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montreal, Quebec, Canada H3T 1E2
    Curr Oncol Rep 6:116-22. 2004
    ..Continuing development and optimization of glutathione analogues will lead to more specific targeting of this system in cancer treatment, allowing an increased therapeutic response...
  50. pmc Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada--a time and motion study
    Gayle A Shinder
    Department of Oncology, McGill University, Gerald Bronfman Centre, 546 Avenue des Pins Ouest, Montreal, Quebec, H2W 1S6, Canada
    BMC Health Serv Res 12:370. 2012
    ....
  51. ncbi [The réseau de recherche sur le cancer: favoring a multi-disciplinary approach]
    Anne Marie Mes-Masson
    Direction du réseau de recherche sur le cancer, Centre de recherche du Centre hospitalier de l Université de Montréal CHUM et Institut du cancer de Montréal, Montreal, Quebec, Canada
    Bull Cancer 93:831-4. 2006
    ..Optimization of resources is made possible by the contributions of basic scientists and clinicians working together towards a unified objective: fighting cancer...
  52. ncbi The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region 4
    Maha Katabi
    McGill Center for Translational Research in Cancer, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada
    Mol Ther 5:170-6. 2002
    ....
  53. doi The biology behind prognostic factors of cutaneous melanoma
    Alan Spatz
    Segal Cancer Centre Jewish General Hospital, Departments of Pathology and Oncology, McGill University, Montreal, Canada
    Curr Opin Oncol 22:163-8. 2010
    ..This review focuses on recent biological data that shed light on the clinico-biological correlations that support the 2010 AJCC melanoma staging system...
  54. ncbi Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy
    Victor Cohen
    Department of Medicine, McGill University, Montreal, Canada
    Clin Cancer Res 9:1611-5. 2003
    ..The aim of the present study was to investigate the association between the MTHFR polymorphism and response to 5-FU and other fluoropyrimidines in patients with metastatic colorectal cancer...
  55. ncbi An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes
    Youssef A Elhaji
    Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2
    Mol Endocrinol 18:1876-86. 2004
    ..Such novel computational modeling may lead to a better understanding of the structure-function relationships and the molecular mechanics of ligand binding not only of the AR-LBD but also of other nuclear receptors...
  56. ncbi Sensitization effect of L-2-oxothiazolidine-4-carboxylate on tumor cells to melphalan and the role of 5-oxo-L-prolinase in glutathione modulation in tumor cells
    X Chen
    McGill Center for Translational Research in Cancer, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    Biochem Pharmacol 56:743-9. 1998
    ..These results indicate a critical interaction between cellular GSH levels and 5-OPase activity that could be important in GSH modulation in therapeutic settings...
  57. ncbi A novel missense mutation in the gamma-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione production
    David Hamilton
    Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada
    Blood 102:725-30. 2003
    ....
  58. ncbi The glutathione system in alkylator resistance
    David Hamilton
    Department of Pharmacology and Therapeutics, McGill University, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    Cancer Treat Res 112:67-87. 2002
  59. ncbi SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors
    L Panasci
    McGill Center for Translational Research in Cancer, Jewish General Hospital, Montreal, Quebec, Canada
    J Clin Oncol 21:232-40. 2003
    ..The purpose of this phase I study was to determine the maximum-tolerated dose (MTD), the toxicity profile, the pharmacokinetics profile, and recommended phase II dose...
  60. ncbi Potential for selective modulation of glutathione in cancer chemotherapy
    X Chen
    Department of Experimental Medicine, McGill University, Montreal, QC, Canada
    Chem Biol Interact 111:263-75. 1998
    ..Preliminary studies suggest that gap junction induction may dramatically deplete GSH concentration in tumor cells and sensitize them to a variety of treatments...
  61. ncbi New taxane analogues from the needles of Taxus canadensis
    J Zhang
    Human Health Research Center, INRS-Institut Armand-Frappier, , 531 Boulevard des Prairies, Laval, , Canada, H7V 1 B7
    J Nat Prod 64:450-5. 2001
    ..Four of these metabolites are new taxane analogues: 7-acetyl-10-deacetyltaxol (1), 2'-acetyl-7-epi-cephalomannine (2), 10-deacetyl-10-oxo-7-epi-cephalomannine (3), and 10-acetylglycollylbaccatin VI (4)...
  62. ncbi A novel parasite-derived suicide gene for cancer gene therapy with specificity for lung cancer cells
    C Trudeau
    Department of Pharmacology, , , , Canada
    Hum Gene Ther 12:1673-80. 2001
    ..Our study shows that this novel system may represent a therapeutic tool for gene prodrug targeting of lung cancer, considering the fact that allopurinol is well tolerated in humans...
  63. ncbi The role of connexin-mediated cell-cell communication in breast cancer metastasis
    G D Carystinos
    Department of Oncology, McGill University Centre for Translational Research in Cancer, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada
    J Mammary Gland Biol Neoplasia 6:431-40. 2001
    ..This is probably because of the loss of cooperation between neighboring cells, leading to cell heterogeneity and cell dissociation in the tumor. The possible involvement of Cx activity during metastasis will be discussed...
  64. ncbi Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors
    R Lapointe
    Centre Hospitalier de l Universite de Montreal, St Luc Hospital, Montreal, Quebec, Canada
    Ann Oncol 16:289-93. 2005
    ..Troxacitabine (Troxatyl) is a novel L-enantiomer nucleoside analog with activity in pancreatic cancer xenograft models...
  65. ncbi Characterization of 5-oxo-L-prolinase in normal and tumor tissues of humans and rats: a potential new target for biochemical modulation of glutathione
    X Chen
    McGill Center for Translational Research in Cancer, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Clin Cancer Res 4:131-8. 1998
    ..In colon tissues, there is no significant difference in 5-OPase level between the normal and tumor tissues. These findings could have implications for both carcinogenesis and therapy...
  66. ncbi Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer
    Christine E Swenson
    Elan Pharmaceuticals, Inc, Princeton, NJ 08540, USA
    Anticancer Drugs 14:239-46. 2003
    ..There was a correlation between the plasma AUC(0-infinity) of total doxorubicin and the degree of myelosuppression in patients receiving conventional doxorubicin, but this correlation was not found in patients receiving TLC D-99...
  67. ncbi A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer
    Mary J Mackenzie
    Hamilton Regional Cancer Centre, 699 Concession St, Hamilton, ON, Canada L8V 5C2
    Invest New Drugs 23:165-70. 2005
    ....
  68. ncbi A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients
    Manijeh Daneshmand
    Ottawa Regional Cancer Centre, Ottawa, Ontario, K1H 1C4 Canada
    Clin Cancer Res 9:2457-64. 2003
    ..Immunohistochemistry for EGFR, activated EGFR, phosphorylated Akt, phosphorylated ERK, p27(Kip1), and beta-catenin was also performed...